TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07902804: A Phase 1, Multicenter, Open-label Study of IBI3043 Treatment in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 604 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07902804 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07902804 Rescue Dossier →